Want to see MDCX full AI Analyst Report?
MDCX Stock Chart & Stats
$0.26
-$0.01(-3.70%)
At close: 4:00 PM EDT
$0.26
-$0.01(-3.70%)
Day’s Range― - ―
52-Week Range$0.08 - $2.78
Previous CloseN/A
Volume1.03M
Average Volume (3M)7.95M
Market Cap
$5.82M
Enterprise Value$29.15M
Total Cash (Recent Filing)$10.70M
Total Debt (Recent Filing)$15.25M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 20, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding63,180,610
10 Day Avg. Volume3,101,308
30 Day Avg. Volume7,954,069
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap5.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$4.00Price Target Upside1438.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pfizer CD228V LicenseThe Pfizer agreement gives Medicus global rights to an early clinical-stage antibody-drug conjugate and provides access to an established linker-payload platform. Potential milestones, royalties, development funding, and Pfizer’s retained options create strategic validation and could support long-term commercialization if clinical execution succeeds.
SkinJect Regulatory ProgressFDA authorization to initiate a planned registrational study represents a meaningful development-stage milestone for SkinJect. Focusing the program on Gorlin syndrome may concentrate resources on a defined population and improve the path toward regulatory evaluation, though clinical success remains necessary.
Teverelix Development EfficiencyThe proposed seamless Phase 2b/3 design could materially reduce the number of patients required for Teverelix development while combining dose optimization, androgen suppression, and cardiovascular evaluation. If accepted by the FDA, this could lower development complexity and improve capital efficiency.
Bears Say
Pre-Revenue LossesMedicus remains pre-commercial, with no reported revenue and losses widening sharply from approximately $5.3 million in 2023 to $39.1 million on a TTM basis. Without an offsetting revenue stream, continued research and development spending leaves profitability and operating leverage dependent on future clinical progress.
Persistent Cash BurnOperating cash flow has been negative in every reported period and reached approximately negative $22.9 million on a TTM basis, while free cash flow was negative $27.4 million. This sustained burn indicates ongoing reliance on external funding to maintain operations and advance the pipeline.
Negative EquityNegative equity indicates that recorded liabilities exceed shareholders’ equity in the latest period, weakening financial flexibility despite low current debt. This condition can constrain capital allocation, increase dependence on future financing, and amplify the financial consequences of continued operating losses.
Medicus Pharma Ltd News
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $0.08 and its highest was $2.78 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $5.82M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
Medicus Pharma Ltd’s upcoming earnings report date is Nov 20, 2026 which is in 40 days.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on Aug 13, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.082.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate is -0.13.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 63,180,610 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went up 6.949%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
MDCX Stock 12 Month Forecast
Average Price Target
$4.00
▲(1438.46% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Palatin Technologies
―
Daré Bioscience
―
Lipocine
―
Citius Pharmaceuticals
―
Ownership Overview
11.57% Insiders
<0.01% Mutual Funds
2.84% Other Institutional Investors
85.58% Public Companies and
Individual Investors